SUWANEE, GA--(Marketwired - Jul 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that
the Company has appointed Alat Medika Indonesia as distributor for dermaPACE® and liaison for clinical trials
participation for Company's wound care product in Indonesia. The expected revenue from this agreement will be north of $1
million over the next three years.
André Mouton, V.P. International Sales and Relations of SANUWAVE, stated, "This decision to engage Alat Medika Indonesia was
made to increase our focus and visibility within Indonesia for the wound care market. It is of the utmost importance that we
partner with distributors that have influence and a good track record within the Indonesian market. It is well known that
diabetes and related concerns need to be addressed within Indonesia and having access to outstanding technology such as
SANUWAVE's within the country is a positive step. We will need speedy access to potential clinical trials to ensure we add value
with our product offering as well as clinical proven outcome. These factors will lead to faster market entry and closer ties with
identified Key Opinion Leaders (KOLs)," concluded André Mouton.
Christian Hainsch, Chief Product Officer of Alat Medika International Group, declared, "Setting the 'PACE®' in
wound healing in Indonesia! A technical milestone in professional wound healing is coming to Indonesia. With dermaPACE, SANUWAVE
developed an innovative medical device for patients suffering from diabetic wounds, ulcer or burn injuries. One of the major
indications for the use of dermaPACE, and most important for Indonesia, is the treatment of diabetic ulcers. With dermaPACE the
regeneration process of tissue from chronic wounds is increased and can be an alternative to amputation or medication based
treatment. Diabetes and other patients benefit from a simple, painless and side-effect free treatment for faster healing and
quicker recovery to improve quality of life," concluded Mr. Hainsch.
SANUWAVE is using this occasion to further educate on our lead wound care product dermaPACE. This Extracorporeal
Shockwave Technology (ESWT) device, based upon electrohydraulic principles, is CE Marked and has enjoyed success in certain
markets within the European Union treating a wide variety of skin conditions such as pressure ulcers, burns, post-operative
wounds, and scar reduction. dermaPACE has been proven, in two US based clinical trials enrolling 336 subjects, to be safe
and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with
dermaPACE reduce in area at superior rates compared to control subjects. dermaPACE exhibits superiority in wound area
reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial
treatment. The use of dermaPACE allows the clinician to more easily, and more cost-effectively, manage wounds. More
importantly, the patient's quality of life improves significantly.
For more information on SANUWAVE's technology, please read our blog, "Shock This", on our website at www.sanuwave.com.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave
technology company initially focused on the development and commercialization of patented noninvasive, biological response
activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio
of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new
vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration.
SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its
lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device
license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S.,
dermaPACE is currently under the FDA's de novo petition review process for the treatment of diabetic foot ulcers.
SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that
its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow
(lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and
chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron®
and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for
SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Alat Medika Indonesia
Being a reliable partner for hospitals, doctors and health care facilities, Alat Medika Group Indonesia brings the
best medical devices to Indonesia. Serving the health care market with dedication, passion and highest quality technology
standards the expert team of Alat Medika provides local medical practitioners, clinics and hospitals with a full range of medical
devices ranging from laboratory equipment to radiology, sonography, laser technology for diagnostics, therapy and health care.
Our team of technical and medical experts helps customers all over Indonesia to identify their needs, supply best in class
medical devices and maintain and service the health care infrastructure.
Contact:
PT. Alat Medika Indonesia
Graha Mustika Ratu Bldg. 10th Floor
Jl. Jend. Gatot Subroto Kav. 74-75
Jakarta 12870 - Indonesia
sales@almed-indonesia.com
Phone: +62 21 83708874
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical
fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that
any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which
are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition
are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven
pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource
issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.